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The incidence of obesity and associated co-morbidities 
such  as  insulin  resistance,  dyslipidemia  and 
cardiovascular  diseases  has  reached  epidemic 
proportions  worldwide.  As  a  result,  new  therapeutic 
options for the treatment of these conditions are clearly 
warranted.  With  the  failure  of  leptin  as  anti-obesity 
therapy,  recent  research  has  focused  on  the  gp130 
receptor  ligands,  in  particular  CNTF,  as  potential 
therapeutic agents for obesity [1]. This cytokine induces 
weight loss and improves glucose tolerance [2] but its 
body  weight  lowering  activity  in  clinical  trials  was 
limited  [3].  On  the  other  hand,  the  effects  of  IL-6 
(another  gp130  ligand)  on  energy  metabolism  remain 
controversial.  Although  IL-6  has  been  proposed  to 
increase insulin resistance, the discovery that IL-6 is a 
myokine produced and released  from skeletal muscle 
during exercise, led many to challenge this concept as 
insulin  action  is  enhanced  immediately  after  exercise 
[4]. In any case clinical use of IL-6 is hampered by its 
potent pro-inflammatory properties. 
 
A  recent  publication  by  our  group  showed  that 
cardiotrophin-1 (CT-1), another member of the gp130 
family  of  cytokines,  plays  a  key  role  in  energy 
metabolism  [5].  This  cytokine  which  is  constitutively 
expressed  in  muscle,  heart,  liver  and  white  adipose 
tissue  (WAT)  has  been  previously  shown  to  exert 
important  cytoprotective  activities.  In  particular  we 
have reported that CT-1 is a natural defence of the liver 
against apoptosis being capable of protecting the liver 
against  immunological  and  ischemic  insults  [6,7].  In 
analyzing  the  metabolic  effects  of  CT-1  we  observed 
that  CT-1  is  a  nutritional-regulated  gene  that  is 
upregulated by fasting and downregulated by refeeding. 
Also we found that ct-1 null mice exhibited a marked 
reduction of energy expenditure and that these animals 
developed mature-onset obesity, insulin resistance and 
hypercholesterolemia, mimicking the human metabolic 
syndrome.  Interestingly,  we  observed  that 
administration of recombinant CT-1 (rCT-1) decreased 
body  weight  by  reducing  food  intake  and  enhancing 
energy expenditure. Moreover, this treatment induced a 
marked  remodeling  of  WAT  as  result  of  increased 
lipolysis, enhanced fatty acid oxidation and stimulation 
of  mitochondrial  biogenesis.  These  changes,  together 
with  upregulation  of  genes  typifying  brown  fat 
phenotype resulted in a sharp decrease of adipocyte size 
and increase oxygen consumption by these cells. On the 
other hand, CT-1 therapy decreased blood glucose in an 
insulin  independent  manner  and  increased  insulin-
stimulated AKT phosphorylation in muscle. CT-1 also 
promoted  fatty  acid  oxidation  in  muscle,  an  effect 
which  was  not  observed  in  AMPKα2
-/-  mice.  In 
agreement  with  all  these  metabolic  effects,  CT-1 
treatment  was  able  to  correct  obesity  and  associated 
diabetes  in  animal  models  of  genetic  and  acquired 
obesity. Thus, CT-1 has emerged as a new player in the 
control of energy metabolism with potential application 
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